TABLE 2.
Baseline characteristics in subjects with HBV not on NAs who did not meet the 2018 AASLD HBV treatment guidelines and developed HCC (no NA/HCC), subjects with HBV on NAs who developed HCC (NA/HCC), and subjects with HBV not on NAs who did not meet 2018 AASLD HBV treatment guidelines and did not develop HCC (no NA/no HCC) compensated cirrhosis with undetectable HBV DNA only
| Factor | Compensated cirrhosis/undetectable HBV DNA/no NA/HCC (115 subjects) n (%) or median (IQR) | Compensated cirrhosis/undetectable HBV DNA/NA/HCC (112 subjects) n (%) or median (IQR) | Compensated cirrhosis/undetectable HBV DNA/no NA/no HCC (111 subjects) n (%) or median (IQR) | p‐Values a |
|---|---|---|---|---|
| ALT (IU/L) | 68 (49–106) | 67 (48–110) | 35 (28–42) | 0.8, <0.001 |
| Male | 80 (70%) | 89 (79%) | 75 (67%) | 0.09, 0.08 |
| Female | 35 (30%) | 23 (20%) | 36 (32%) | 0.09, 0.08 |
| Asian | 48 (42%) | 87 (78%) | 82 (74%) | <0.001, <0.001 |
| White | 30 (26%) | 11 (10%) | 13 (12%) | 0.002, 0.007 |
| Hispanic | 4 (3%) | 0 (0%) | 5 (4%) | 0.01, 0.7 |
| Age (years) | 62 (56–70) | 60 (50–68) | 46 (37–53) | 0.1, <0.001 |
| ALP (U/L) | 129 (90–180) | 131 (113–131) | 79 (64–95) | 0.2, <0.001 |
| AST (IU/L) | 74 (51–119) | 74 (47–122) | 26 (22–33) | 0.6, <0.001 |
| TB (mg/dl) | 1.1 (0.7–1.9) | 1.02 (0.8–1.7) | 0.9 (0.7–1.02) | 0.8, <0.001 |
| INR | 1.3 (1.1–1.4) | 1.2 (1.1–1.3) | 1.1 (1.05–1.1) | 0.08, <0.001 |
| NAs (mmol/L) | 137 (136–139) | 139 (137–143) | 139 (138–140) | <0.001, <0.001 |
| Platelets (K/ul) | 128 (88–194) | 146 (116–194) | 193 (154–226) | 0.04, <0.001 |
| Albumin (g/dl) | 3.3 (2.7–3.7) | 3.7 (3–4) | 4.1 (3.8–4.3) | 0.001, <0.001 |
| ALD | 38 (33%) | 35 (31%) | 4 (4%) | 0.08, <0.001 |
| HCV | 16 (14%) | 7 (6%) | 8 (7%) | 0.08, 0.1 |
| NAFLD | 27 (23%) | 22 (20%) | 16 (14%) | 0.5, 0.09 |
| HIV | 3 (3%) | 1 (1%) | 3 (3%) | 0.6, 1 |
| HDV | 0 (0%) | 0 (0%) | 0 (0%) | 1, 1 |
a
p‐Values comparing NA/HCC to no NA/HCC, and no NA/no HCC to no NA/HCC, respectively.